NCT05775601View on ClinicalTrials.gov

18F-LY3950321-01 Biodistribution and Safety Study

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

April 4, 2023

Study Completion Date

April 4, 2023

Conditions
Diagnostic Agent Adverse ReactionRadiation Exposure
Interventions
DRUG

18F-LY3950321

3 millicuries (±1 mCi)

PROCEDURE

PET Scan

positron emission tomography (PET) scan

Trial Locations (1)

06510

Invicro, LLC, New Haven

Sponsors
All Listed Sponsors
lead

Avid Radiopharmaceuticals

INDUSTRY